Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development.

Brockmann, Rouen; Nixon, Joanna; Love, Bryan L; Yunusa, Ismaeel

Brockmann, Rouen; Nixon, Joanna; Love, Bryan L; Yunusa, Ismaeel.

Afiliación

Brockmann R; University of South Carolina College of Pharmacy, Columbia, SC, USA.
Nixon J; University of South Carolina College of Pharmacy, Columbia, SC, USA.
Love BL; University of South Carolina College of Pharmacy, Columbia, SC, USA.
Yunusa I; Center for Outcomes Research and Evaluation, University of South Carolina College of Pharmacy, Columbia, USA.

Lancet Reg Health Am ; 20: 100467, 2023 Apr.

Article en En | MEDLINE | ID: mdl-36908502

Palabras clave

Aducanumab; Alzheimer's disease; Amyloid ß plaque

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Prognostic_studies Idioma: En Revista: Lancet Reg Health Am Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google